Synergistic Activity between Ravuconazole and the Echinocandin Micafungin in Treatment of Experimental Pulmonary Aspergillosis

R. PETRAITIENE1, V. PETRAITIS 1, A. SARAFANDI 1, A. KELAHER 1, C. A. LYMAN 1, T. SEIN 1, A. H. GROLL 1, D. MICKIENE 1, J. BACHER 2, T. J. WALSH 1

Author address: 

1NCI, NIH, Bethesda, MD, 2OD, ORS, NIH, Bethesda, MD.

Abstract: 

Background: Micafungin (MICA) is a novel injectable echinocandin with broad-spectrum fungicidal activity against Candida and fungistatic activity against Aspergillus spp. In order to test the hypothesis that the efficacy of an echinocandin can be augmented by an antifungal triazole, we studied the antifungal activity of MICA in combination with ravuconazole (RAV) against experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits. Methods: Treatment groups consisted of MICA at 1 (MICA1), RAV at 2.5 (RAV2.5) mg/kg/day, MICA1+RAV2.5 (MICA+RAV), and untreated controls (UC). Results: There was significant reduction of residual fungal burden (CFU/g) in MICA+RAV treated rabbits in comparison to RAV2.5 (p
2002

abstract No: 

M-857

Full conference title: 

42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 42nd